Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

Marinella Clerico, Stefania De Mercanti, Carlo Alberto Artusi, Luca Durelli, Robert T. Naismith

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta-treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication. andcopy; SAGE Publications.

Original languageEnglish
Pages (from-to)874-876
Number of pages3
JournalMultiple Sclerosis
Volume23
Issue number6
DOIs
StatePublished - May 1 2017

Keywords

  • Multiple sclerosis
  • alemtuzumab
  • cytomegalovirus
  • cytomegalovirus reactivation
  • herpes virus
  • multiple sclerosis treatment

Fingerprint Dive into the research topics of 'Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab'. Together they form a unique fingerprint.

  • Cite this